



Capítulos en Libros

- Keller GA, Villa Etchegoyen MC, Di Girolamo G. Prolongación del Intervalo QTc inducida por Fármacos. Manual de Buenas Practicas de Farmacovigilancia (2016). Página 257-284.
- Keller GA, Villa Etchegoyen MC, Di Girolamo G. Experiencia de un Centro Universitario de Farmacovigilancia. Manual de Buenas Practicas de Farmacovigilancia (2016). Página 257-284.
- Keller GA, Di Girolamo G. Prolongación del Intervalo QT inducida por fármacos. En "Farmacovigilancia: Hacia una mayor seguridad en el uso de medicamentos", 1º Edición, Córdoba, Raquel Herrera Comoglio Ediciones, 2012. ISBN 978-987-28104-1-2.
- Keller GA, Di Girolamo G. Reacciones Adversas Cardiovasculares. En "Manual de Farmacovigilancia Hospitalaria", Red de Farmacovigilancia Hospitalaria de la Ciudad de Buenos Aires, Buenos Aires, 2012.

Publicaciones en Revistas Indexadas en Medline

1. Bril F, Castro V, Gomez Centurion I, Espinosa J, Keller GA, Gonzalez CD, Soler C, Lopez Saubidet C, Di Girolamo G, Alvarez PA. Assessing the Burden of Drug Interactions in Kidney Transplant Patients. Curr Drug Saf. 2016; in press.
2. Keller GA, Villa Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, Diez RA, Di Girolamo G. Meperidine Induced QTc-Interval Prolongation: Prevalence, Risk Factors and Correlation to Plasma Drug and Metabolite Concentrations. Curr Drug Saf. 2016; in press.
3. Keller GA, Villa Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, Diez RA, Di Girolamo G. Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations. Curr Drug Saf. 2016; in press.
4. Farias J, Keller GA, Papouchado M, Criscuolo ME, Diez RA, Di Girolamo G. Relative bioavailability between two teriparatide formulations in healthy volunteers. Int J Clin Pharmacol Ther 2016; in press.
5. Keller GA, Czerniuk P, Bertuola R, Villa Etchegoyen MC, Mendez M, Gimenez MI, Di Girolamo G. Comparative bioavailability of 2 tablet formulations of emtricitabine /tenofovir in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study. Int J Clin Pharmacol Ther 2016; 54(1); in press.
6. Keller GA, Alvarez PA, Ponte ML, Belloso WH, Bagnes C, Gonzalez CD, Villa Etchegoyen MC, Diez RA, Di Girolamo G. Drug-induced QTc interval prolongation: A multicenter study to detect drugs and clinical factors involved in every day practice. Curr Drug Saf. 2016;11:86-98.
7. Oliveri B, Mastaglia SR, Brito GM, Seijo M, Keller GA, Somoza J, Diez RA, Di Girolamo G. Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. Eur J Clin Nutr. 2015 Mar 18.
8. Keller GA, Fabian L, Gomez M, Gonzalez CD, Diez RA, Di Girolamo G. Age-Distribution and genotype / phenotype correlation for N-acetyltransferase in Argentine children under isoniazid treatment. Int J Clin Pharmacol Ther 2014; 52(4): 292-302.
9. Alvarez PA, Bril F, Castro V, Meiville I, Gonzalez CD, Gomez Centurion I, Parejas G, Soler Riera C, Lopez Saubidet C, Di Girolamo G, Keller GA. Adverse Drug Reactions



- as a Reason for Admission to an Internal Medicine Ward in Argentina. *Int J Risk Saf Med* 2013; 25(3):185-92.
10. Alvarez PA, Egozcue J, Sleiman J, Moretti L, Di Girolamo G, Keller GA. Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate. *Curr Drug Saf* 2012;7(1):24-9.
 11. Keller GA, Di Girolamo G, Alvarez PA. Pharmacovigilance and the cardiovascular system: two sides to every story. *Curr Drug Saf* 2011;6(4):224-9.
 12. Keller GA, Czerniuk P, Bertuola R, de Mena F, Simoni MV, Assefi AR, Di Girolamo G. Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study. *Curr Med Res Opin* 2011;27(11):2203-11.
 13. Keller GA, Czerniuk P, Bertuola R, Spatz JG, Assefi AR, Di Girolamo G. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study. *Clin Ther* 2011;33(4):500-10.
 14. Altman R, Scazziotto AS, Pons S, Herrera L, Keller GA, Assefi AR, Di Girolamo G. Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity. *Curr Med Res Opin*. 2011 Jan;27(1):1-9.
 15. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of Two Tablet Formulations of Clopidogrel in Healthy Argentinian Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study. *Clinical Therapeutics* 2010; 32(1):161-170.
 16. Ponte ML, Keller GA, Di Girolamo G. Mechanisms of Drug Induced QT Interval Prolongation. *Current Drug Safety* 2010; 5(1):44-53
 17. Keller GA, Di Girolamo G. Antihistamines: Past Answers and Present Questions. *Current Drug Safety* 2010; 5(1):58-64
 18. Keller GA, Di Girolamo G. Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors. *Current Drug Safety* 2010; 5(1):73-78
 19. Keller GA, Ponte ML, Di Girolamo G. Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation. *Current Drug Safety* 2010; 5(1):105-111
 20. Di Girolamo G, Keller GA, de los Santos AR, Schere D, Gonzalez CD. Bioequivalence of Two Levothyroxine Tablet Formulations Without and With Mathematical Adjustment for Basal Thyroxine Levels in Healthy Argentinian Volunteers: A Single-Dose, Randomized, Open-Label, Crossover Study. *Clinical Therapeutics* 2008;30(11):2015-23.
 21. Di Girolamo G, Kauffman MA, Gonzalez E, Papouchado M, Ramirez A, Keller G, Carbonetto C, Dabsys S, Vidal A, Sterin-Prync A, Diez RA. Bioequivalence of two subcutaneous pharmaceutical products of interferon beta 1a. *Arzneimittel-Forschung* 2008;58(4) 193-198.
 22. Di Girolamo G, Opezzo JAW, Lopez MI, Schere F, Keller G, Gonzalez CD, de los Santos MC. Relative bioavailability of new formulation of paracetamol effervescent powder containing sodium bicarbonate versus paracetamol tablets: a comparative pharmacokinetic study in fed subjects. *Expert Opin Pharmacother* 2007;8(15):1-9
 23. Gonzalez C, Beruto V, Keller G, Santoro S, Di Girolamo G. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. *Expert Opin Investig Drugs*. 2006;15(8):887-95.



Número Especial en Revista:

Debe destacarse, que el trabajo desarrollado por el equipo de farmacovigilancia en relación a la prolongación del intervalo QT, motivó que fuera elegido para encarar una revisión extensa en un número especial de la revista *Current Drug Safety* dedicado a dicho efecto adverso. Dicho número se encuentra actualmente disponible para descarga gratuita, y se compone de los siguiente artículos:

- [Di Girolamo G. Drug-induced at interval prolongation: clinical, safety and regulatory updaes. Curr Drug Saf. 2010;5\(1\):41-3.](#)
- [Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010;5\(1\):44-53.](#)
- [Giorgi MA, Bolaños R, Gonzalez CD, Di Girolamo G. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf. 2010;5\(1\):54-7.](#)
- [Keller GA, Di Girolamo G. Antihistamines: past answers and present questions. Curr Drug Saf. 2010;5\(1\):58-64.](#)
- [Taira CA, Opezzo JA, Mayer MA, Höcht C. Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf. 2010;5\(1\):65-72.](#)
- [Keller GA, Di Girolamo G. Prokinetic agents and QT prolongation: a familiar scene with new actors. Curr Drug Saf. 2010;5\(1\):73-8.](#)
- [Gonzalez CD, de Sereday M, Sinay I, Santoro S. Endocrine therapies and QTc prolongation. Curr Drug Saf. 2010;5\(1\):79-84.](#)
- [Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf. 2010;5\(1\):85-92.](#)
- [Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf. 2010;5\(1\):93-6.](#)
- [Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5\(1\):97-104.](#)
- [Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf. 2010;5\(1\):105-11.](#)